<DOC>
	<DOCNO>NCT02634151</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , tolerability multiple dos gemcabene 600 mg QD compare placebo patient hypercholesterolemia adequately control high-intensity moderate-intensity stable statin therapy . Patients HeFH , ASCVD , otherwise uncontrolled , may include baseline LDL-C value ≥ 100 mg/dL . Subjects randomize 1:1 gemcabene 600 mg QD placebo .</brief_summary>
	<brief_title>A 12-Week , Phase 2 Study Gemcabene Hypercholesterolemia Patients Stable Moderate High-Intensity Statins</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>1 . Provision write sign inform consent ( subject legal guardian ) prior studyspecific procedure ; 2 . Male female ( neither pregnant lactating ) ≥ 18 year age time consent ; 3 . Currently stable , lowfat , lowcholesterol diet combination allow statin dos describe Table 1 , without ezetemibe 10 mg QD least 12 week prior Screening Visit ; 4 . Fasting LDLC value ≥ 100 mg/dL ( 2.59 mmol/L ) Screening Visit ; 5 . Physical examination , include vital sign , within normal limit clinically acceptable Investigator ; 6 . Weight ≥ 50 kg ; body mass index ( BMI ) ≤ 45 kg/m2 7 . Subjects Type 2 diabetes take antihyperglycemic agent must stable regimen least 3 month , plan change medication study duration . Exclusion Criteria 1 . Abnormal liver function test PreScreening Screening Visit ( AST ALT ) &gt; 2x ULN ( upper limit normal ) , total bilirubin &gt; 1.5x ULN , alkaline phosphate &gt; 2x ULN base appropriate age gender normal value . Subjects bilirubin &gt; 1.5x ULN history Gilbert 's syndrome may include ; relfexive direct bilirubin test use confirm Gilbert 's syndrome ; 2 . Moderate ( Grade B ) severe ( Grade C ) chronic hepatic impairment accord ChildPugh classification ; 3 . Active liver disease ( e.g . cirrhosis , alcoholic liver disease , hepatitis B , hepatitis C , automimmune hepatitis , liver failure , liver cancer ) , history liver transplant , know diagnosis HIV AIDS ; 4 . Triglyceride value ≥ 500 mg/dL PreScreening Visit Screening Visit ; 5 . Moderate severe renal insufficiency define estimate GFR &lt; 60mL/min/1.73m ( calculate use Chronic Kidney Disease Epidemiology Collaboration equation ) PreScreening Visit Screening Visit ; 6 . Abnormal urinalysis ( proteinuria great trace male nonmenstruating female great trace hematuria ) confirm reflexive urine protein : creatinine ration test ; 7 . Uncontrolled thyroid disease ; hyperthyroidism hypothyroidism define thyroid stimulate hormone ( TSH ) low limit normal &gt; 1.5x ULN , respectively , base result PreScreening Visit Screening Visit . If control , treatment stable least 3 month prior Screening ; 8 . Type 1 diabetes mellitus uncontrolled type 2 diabetes mellitus ( hemoglobin A1c value &gt; 8.5 % base result PreScreening Screening Visit , take thiazolidinedione ( i.e . pioglitazone rosiglitazone ) ; 9 . New York Heart Association Class III IV heart failure ; 10 . Myocardial infarction , severe unstable angina pectoris , coronary angioplasty , coronary artery bypass graft , major cardiovascular event result hospitalization within 3 month Screening Visit . Subjects adequately treat stable angina , per Investigator assessment , may include ; 11 . Uncontrolled cardiac arrhythmia prolong QT Screening Visit Day 1 prior dose ECG ( QTcF &gt; 450 msec men &gt; 470 msec woman ) know family history prolong QT unexplained sudden cardiac death ; 12 . Uncontrolled hypertension , define sit systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg , confirm repeat measurement ; 13 . Currently receive cancer treatment , Investigator 's opinion , risk relapse recent cancer ; 14 . Inadequate washout PCSK9 inhibitor ( 8 week prior Screening Visit ) , fibrate lipidregulating agent ( 6 week prior Screening Visit ) , niacin ( 4 week prior Screening Visit ) , lipidregulating therapy bile acid sequestrants ( 4 week prior Screening Visit ) ; 15 . Hypersensitivity history significant adverse reaction fibrate lipidregulating agent ; 16 . Use excluded medication supplement ( e.g . potent cytochrome P450 [ CYP ] 3A4 inhibitor describe Appendix D ; 17 . History drug alcohol abuse within past year inabilty comply protocol requirement , include subject restriction ( see Section 5.6.3 ) ; 18 . Previously treat gemcabene ( CI1027 ) , participation another clinical study investigational agent device concurrently within 1 month prior Screening Visit , use investigational agent within 1 month 5 halflives ( know ) , whichever longer , prior Screening Visit ; 19 . Any finding , opinion Investigator , would compromise subject 's safety participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>LDL‐C</keyword>
	<keyword>Lipid Regulator</keyword>
</DOC>